New drug combo aims to boost head and neck cancer treatment
NCT ID NCT05366166
First seen Jan 30, 2026 · Last updated May 23, 2026 · Updated 14 times
Summary
This study tests whether giving two drugs, pembrolizumab and olaparib, before and after standard chemoradiation can help people with advanced head and neck cancer. About 45 adults will take part. The goal is to see if this approach delays cancer growth or improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Indiana University Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
Medical University of South Carolina (MUSC)
Charleston, South Carolina, 29425, United States
-
UNC Lineberger
Chapel Hill, North Carolina, 27514, United States
-
University of Louisville, Brown Cancer Center
Louisville, Kentucky, 40202, United States
Conditions
Explore the condition pages connected to this study.